Table 4 Pathological characteristics and analytical performances of each method
WT | V600 mutation | Invalid result | |||||||
|---|---|---|---|---|---|---|---|---|---|
Specimen characteristics | HRM | Sanger sequencing | THxID™-BRAF test | HRM | Sanger sequencing | THxID™-BRAF test | HRM | Sanger sequencing | THxID™-BRAF test |
Tumor percentage | |||||||||
Samples <80% | 12 | 10 | 11 | 1 | 1 | 2 | 0 | 2 | 0 |
Samples ≥80% | 57 | 52 | 55 | 41 | 45 | 44 | 0 | 3 | 1 |
Melanin rate | |||||||||
Sample 0 | 62 | 56 | 59 | 40 | 45 | 45 | 0 | 4 | 1 |
Sample + (>20%) | 4 | 3 | 4 | 1 | 1 | 1 | 0 | 1 | 0 |
Sample ++ (20 to 50%) | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
Sample +++ (≤50%) | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Tumor necrosis | |||||||||
Sample 0 | 55 | 49 | 53 | 34 | 38 | 39 | 0 | 5 | 0 |
Sample + (<10%) | 10 | 9 | 9 | 5 | 6 | 5 | 0 | 0 | 1 |
Sample ++ to +++ (≥10%) | 4 | 4 | 4 | 2 | 2 | 2 | 0 | 0 | 0 |